Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00818441 |
This study will explore the safety and efficacy of the oral PanHER inhibitor PF-00299804 in patients with adenocarcinoma of the lung who are either non-smokers (<100 cigarette, cigar or pipe lifetime) or former light smokers ( less than 10 pack-years and stopped at least 15 years)
Condition | Intervention | Phase |
---|---|---|
Carcinoma, Non-Small Cell |
Drug: PF-00299804 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase 2, Open Label, Trial Of PF-00299804 In Untreated Advanced Adenocarcinoma Of The Lung In Never Or Former Light Smokers |
Estimated Enrollment: | 80 |
Study Start Date: | January 2009 |
Estimated Study Completion Date: | January 2012 |
Estimated Primary Completion Date: | June 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
PF-00299804: Experimental
not specified
|
Drug: PF-00299804
PF-00299804 at 45 mg daily by continuous oral dosing
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Pfizer Oncology Clinical Trial Information Service | 1-877-369-9753 | PfizerCancerTrials@emergingmed.com |
Contact: Pfizer CT.gov Call Center | 1-800-718-1021 |
United States, South Carolina | |
Pfizer Investigational Site | |
Easley, South Carolina, United States, 29640 | |
Pfizer Investigational Site | |
Greenville, South Carolina, United States, 29605 | |
Pfizer Investigational Site | |
Greenville, South Carolina, United States, 29615 | |
Pfizer Investigational Site | |
Spartanburg, South Carolina, United States, 29307 | |
Pfizer Investigational Site | |
Seneca, South Carolina, United States, 29672 | |
Pfizer Investigational Site | |
Greet, South Carolina, United States, 29650 |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Responsible Party: | Pfizer, Inc. ( Director, Clinical Trial Disclosure Group ) |
Study ID Numbers: | A7471017 |
Study First Received: | January 5, 2009 |
Last Updated: | January 6, 2009 |
ClinicalTrials.gov Identifier: | NCT00818441 |
Health Authority: | United States: Food and Drug Administration |
lung cancer
adenocarcinoma
untreated
nonsmoker
former smoker |
Adenocarcinoma of lung Lung Neoplasms Adenocarcinoma Neoplasms, Glandular and Epithelial Carcinoma |
Neoplasms Neoplasms by Histologic Type |